(PRESS RELEASE) Oakland, CA – March 3, 2016 – Omicia, the leading provider of clinical genome interpretation software and services, announced that Matt Tindall has been appointed CEO and a member of the company’s Board of Directors, effective March 1st, 2016. Mr. Tindall will be responsible for propelling Omicia through its next phase of development as the company and its partners leverage its Opal Clinical software platform to expedite diagnosis and improve medical outcomes.
Mr. Tindall has more than two decades of healthcare experience spanning management, corporate development, strategy consulting, digital marketing and sales. Prior to Omicia, he served as general manager of the Consumer Solutions division of IMS Health, a leading global information and technology services company. During his tenure with the company, Mr. Tindall built an industry-leading SaaS business in the digital health space, led the acquisition and integration of a global technology company and assisted in the company’s transition to becoming a public company (NYSE:IMS). Prior to IMS Health, he held positions with Celera Genomics, Genzyme Corporation and Digitas Health.
“Matt’s commercial experience, leadership and vision are perfectly matched to capture the increasing demand for Omicia’s Opal Clinical platform and services,” said John Stuelpnagel, Co-Founder and Chairman of the Omicia Board of Directors. “Our landmark relationship with Genomics England in which Omicia is delivering and demonstrating its superior, scalable technology and deep expertise is just the beginning of an exciting journey for the company. We’re confident that Matt has the proven ability to drive innovation and growth, execute corporate strategy and deliver results.”
“Opal Clinical was developed in collaboration with leading clinical testing labs, and is well-positioned to become the industry’s default genomic analytics engine,” says Mr. Tindall. “The team recognizes the unique opportunity they have to help transform the delivery of human healthcare by powering precision medicine initiatives globally. I’m honored to lead, advance and expand the founders’ vision from here.”
Omicia will be exhibiting at the ACMG conference in Tampa, March 9-11th (Booth #517) and presenting a workshop on “Software-Enabled Application of the ACMG Interpretation Guidelines” on Thursday, March 10 at 11:40am in Exhibit Theater #2.
About Omicia, Inc.
Omicia delivers a market-leading software platform that enables analysis, interpretation, and reporting on genomic data to expedite diagnosis and improve medical outcomes. Omicia’s products are in use at more than 500 world-class academic and clinical institutions worldwide. By accelerating understanding of the genetic basis of disease, drug response, and health, Omicia is unlocking the potential of individualized medicine. Headquartered in Oakland, California with an office in the UK, Omicia was founded by renowned industry veterans with a deep understanding of technology, genomics, and diagnostics. Investors include ARTIS Ventures, Acadia Woods, Bay City Capital, Buchanan Investments, Casdin Capital, and Apoletto. For more information, visit www.omicia.com.